Vor Biopharma (NYSE:VOR) Receives “Outperform” Rating from Oppenheimer

Oppenheimer restated their outperform rating on shares of Vor Biopharma (NYSE:VOR) in a research report sent to investors on Friday morning,Benzinga reports. The firm currently has a $8.00 target price on the stock.

A number of other research analysts have also recently issued reports on VOR. Wedbush reiterated an “outperform” rating and issued a $7.00 target price on shares of Vor Biopharma in a research report on Thursday. Stifel Nicolaus decreased their price target on shares of Vor Biopharma from $12.00 to $5.00 and set a “buy” rating on the stock in a report on Friday. HC Wainwright dropped their price objective on shares of Vor Biopharma from $17.50 to $13.00 and set a “buy” rating for the company in a research note on Friday. Finally, JMP Securities reaffirmed a “market outperform” rating and set a $12.00 target price on shares of Vor Biopharma in a research note on Tuesday, December 10th. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat, Vor Biopharma presently has an average rating of “Buy” and a consensus target price of $8.86.

Vor Biopharma Stock Performance

Shares of VOR opened at $0.87 on Friday. Vor Biopharma has a 52-week low of $0.63 and a 52-week high of $2.43. The firm has a market cap of $59.75 million, a price-to-earnings ratio of -0.53 and a beta of -0.40. The business’s fifty day moving average is $1.22 and its 200-day moving average is $1.01.

Hedge Funds Weigh In On Vor Biopharma

Large investors have recently modified their holdings of the business. RA Capital Management L.P. grew its stake in shares of Vor Biopharma by 74.3% in the fourth quarter. RA Capital Management L.P. now owns 39,646,039 shares of the company’s stock worth $44,007,000 after purchasing an additional 16,897,159 shares during the last quarter. Lynx1 Capital Management LP acquired a new position in Vor Biopharma during the 4th quarter worth about $707,000. Two Sigma Investments LP grew its position in shares of Vor Biopharma by 18.9% in the 4th quarter. Two Sigma Investments LP now owns 163,064 shares of the company’s stock valued at $181,000 after buying an additional 25,930 shares during the last quarter. Northern Trust Corp increased its stake in shares of Vor Biopharma by 39.0% in the fourth quarter. Northern Trust Corp now owns 157,617 shares of the company’s stock valued at $175,000 after buying an additional 44,252 shares during the period. Finally, Trustees of Columbia University in the City of New York bought a new position in shares of Vor Biopharma during the fourth quarter worth about $102,000. Institutional investors own 97.29% of the company’s stock.

Vor Biopharma Company Profile

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.